This review assessed the effectiveness of drug treatments in preventing bone erosion (determined from X-rays) in rheumatoid arthritis. The authors concluded that cyclosporine, infliximab, sulphasalazine, leflunomide, methotrexate, parenteral gold, corticosteroids, auranofin and IL-1-RA are more effective than placebo. This conclusion appears reliable. Conclusions about relative effectiveness of different drugs were derived from indirect comparisons and may not be reliable.
papers were assessed for quality, or how many reviewers performed the quality assessment.
Data extraction
Two authors independently extracted the efficacy data from the published reports. Any disagreements were resolved by discussion involving a third investigator. The primary outcome, the radiographic scoring of bone erosion in joints, was reported using a number of scoring systems. Where necessary, trialists were contacted for further information.
Methods of synthesis
How were the studies combined? To allow the direct comparison and pooling of studies, the authors of the review calculated two dimensionless outcome measures: the standardised mean difference (SMD; changes in erosion score) and the odds of worsening X-ray scores (progression of erosion). Details were given in the review. Only trials of the same agent were pooled. To minimise possible heterogeneity due to different treatment duration, the trials were pooled using follow-up data as close to 12 months as possible. Pooled effect sizes for the SMD and the odds of worsening X-ray scores were calculated, along with 95% confidence intervals, using a fixed-effect model. Standard t-tests were use to compare the mean treatment effects between X-ray trials and disease activity trials. The results were ranked in order of the pooled SMD. Superiority of one treatment over another was defined as the point estimate of the inferior agent not including the 95% confidence interval of the superior agent.
How were differences between studies investigated?
Tests for heterogeneity were performed using the Mantel-Haenszel method.
Results of the review
Twenty-five trials (n=3,907) were included in the review.
There were 5 trials of corticosteroids; 3 of parenteral gold; 2 of sulphasalazine; 2 of leflunomide; 2 of auranofin; 2 of hydroxychloroquine; 2 of chloroquine; 2 of pamidronate; and one each of cyclosporin, infliximab, methotrexate, IL-1-RA, minocycline, cyclophosphamide, and D-penicillamine.
The quality scores of the included studies ranged from 7 to the maximum 12. There was no significant association between quality score and efficacy.
For changes in erosion score, in rank order, cyclosporin, infliximab, sulphasalazine, leflunomide, methotrexate, parenteral gold, corticosteroids, auranofin and IL-1-RA were statistically better then placebo. Only infliximab demonstrated superiorty over any other agent; it was superior to methotrexate, parenteral gold, corticosteroids, auranofin and IL-1-RA.
For effect of pharmaceutical treatment on the progression of erosions, in rank order, infliximab, leflunomide, methotrexate, parenteral gold, sulphasalazine and corticosteroids were statistically better then placebo. Only infliximab demonstrated superiority over any other agent; it was superior to parenteral gold, corticosteroids, auranofin and IL-1-RA.
